Peptides DB
Research-centric peptide and protocol reference hub
Study 1 of 6Sermorelin literaturePubMed · Observational2025

Growth hormone - releasing hormone antagonists induce autophagy in cancer cells.

The study indicates that the GHRH antagonist JV-1-36 can induce autophagy in certain cancer cells, but the implications for cancer treatment remain unclear without further research.

Read at PubMedAdd to compare

Where it sits

this study against the rest of the sermorelin corpus
2
Preclinical
4
Observational · this one
0
Open-label
0
Randomised
0
Reviews

Summary and findings

This study evaluated the effects of the GHRH antagonist JV-1-36 on autophagy in MDA-MB-468 and A549 cancer cells. The treatment resulted in elevated expression levels of autophagy-related proteins ATG-5, ATG-3, ATG-7, and ATG-16L1. No effects were observed in MCF-7 cells, which do not express GHRH receptors.

How much of this paper we could read: partial text (0.50). We had some abstract detail. Check the source for anything decisive. What this means →
Not reported in abstract.2025

Abstract

The authors’ words, as PubMed supplied them

GHRH antagonists (GHRHAnt) were developed to suppress cancers and have been associated with robust anti-inflammatory and anti-oxidative activities. The mechanisms involved in those effects are not completely understood. MDA-MB-468 and A549 cancer cells, which express GHRH receptors, were treated with GHRHAnt JV-1-36, to evaluate the effects of that compound in autophagy. JV-1-36 induces autophagy in MDA-MB-468 and A549 cells since exposure to the aforementioned peptide elevated the expression levels of the autophagy-related protein (ATG) - 5, ATG - 3, ATG - 7, and ATG-16L1. In contrast, MCF-7 cells - which do not express GHRH receptors - did not respond to GHRHAnt. Our findings suggest that the beneficial effects of GHRHAnt in cancers may involve autophagy. Further studies will attempt to delineate the underlying mechanisms.

Background

The paper addresses the role of growth hormone-releasing hormone antagonists in inducing autophagy within cancer cells. Prior research has suggested that autophagy can play a dual role in cancer, potentially promoting cell survival or death depending on the context. Understanding how these antagonists influence autophagy could provide insights into their potential therapeutic applications in oncology.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Not reported in abstract.

Limitations

  • Not reported in abstract.

Elsewhere in the Sermorelin corpus

BAnterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report.europepmc · 2026 · n=1HumanCMesenchymal Stem cell therapy with GHRH receptor analog resolves post-stroke vasogenic edema via modulating AQP4 and mitochondria-ER crosstalk.europepmc · 2026 · n=30 · Not reported in abstract.AnimalBAnterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report.PubMed · 2026 · Not reported in abstract.HumanDSemantic Scholar search for SermorelinSemanticScholar · 2010CGrowth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells.PubMed · 2024 · Not reported in abstract.In vitro